Company profile
Summit Therapeutics Inc.
NASDAQ:SMMTBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ivonescimab | phase3 | — | 1 | active |
| RIDINILAZOLE | phase2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02056808 | phase1 | completed | 2013-11-01 | 2014-05-01 | Summit Therapeutics | A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD) |
| NCT02784002 | phase2 | completed | 2014-12-01 | 2016-08-01 | Summit Therapeutics | A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) |
| NCT02092935 | phase2 | completed | 2014-04-01 | 2015-10-01 | Summit Therapeutics | A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD) |
| NCT05899608 | phase3 | recruiting | 2023-10-26 | 2028-12-31 | Summit Therapeutics | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients |
| NCT06767514 | phase3 | recruiting | 2025-02-27 | 2028-04-01 | Summit Therapeutics | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 |
FDA applications (0)
No records yet.